Literature DB >> 23588881

Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.

Rosario Peluso1, Giovanni Cafaro, Alessandro Di Minno, Salvatore Iervolino, Pasquale Ambrosino, Gelsy Lupoli, Matteo Nicola Dario Di Minno.   

Abstract

Psoriatic arthritis is an inflammatory rheumatic disorder, which occurs in patients with skin and/or nail psoriasis. In psoriatic arthritis, the importance of biologic mediators modulating inflammatory reaction, such as tumor necrosis factor, and the knowledge on their role in the pathogenesis of psoriatic arthritis influence the therapeutic choices. In the last years, the introduction of biologic drugs has greatly changed the treatment of psoriasis and psoriatic arthritis. In fact, tumor necrosis factor-α blockers demonstrated an effective action in the treatment of both skin and joint manifestations of psoriatic arthritis, but they have some adverse effects. The aim of this review is to revisit the literature data on adverse effects of tumor necrosis factor-α blockers in patients with psoriatic arthritis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23588881     DOI： 10.1007/s10067-013-2252-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   3.650


  138 in total

1.  Pulmonary sarcoidosis developing during infliximab therapy.

Authors:  Finbar D O'Shea; Theodore K Marras; Robert D Inman
Journal:  Arthritis Rheum       Date:  2006-12-15

2.  Relapse of sarcoidosis upon treatment with etanercept.

Authors:  G H Louie; P Chitkara; M M Ward
Journal:  Ann Rheum Dis       Date:  2008-06       Impact factor: 19.103

3.  Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.

Authors:  Elias Spanakis; Prodromos Sidiropoulos; John Papadakis; Emmanuel Ganotakis; George Katsikas; Stylianos Karvounaris; Argyro Bizaki; Heraklis Kritikos; Dimitrios T Boumpas
Journal:  J Rheumatol       Date:  2006-10-01       Impact factor: 4.666

4.  [Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis].

Authors:  Mathieu Sacquépée; Vincent Rouleau; Jean-François Cantin; Nicolas Quirin; Yves Doussy; Jean-Claude Valéry; Cristina Picu; Jean-Michel Tivollier
Journal:  Nephrol Ther       Date:  2010-07-04       Impact factor: 0.722

Review 5.  Pro-inflammatory cytokines and adipose tissue.

Authors:  S W Coppack
Journal:  Proc Nutr Soc       Date:  2001-08       Impact factor: 6.297

6.  Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.

Authors:  Laia Gifre; Virginia Ruiz-Esquide; Antoni Xaubet; José A Gómez-Puerta; M Victoria Hernández; Raimon Sanmartí
Journal:  Arch Bronconeumol       Date:  2010-07-17       Impact factor: 4.872

7.  Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature.

Authors:  Jean-Marie Berthelot; Michel De Bandt; Philippe Goupille; Elisabeth Solau-Gervais; Frédéric Lioté; Vincent Goeb; Isabelle Azaïs; Antoine Martin; Béatrice Pallot-Prades; Yves Maugars; Xavier Mariette
Journal:  Joint Bone Spine       Date:  2008-12-06       Impact factor: 4.929

8.  Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.

Authors:  Adam C Esser; Andy Abril; Scott Fayne; John A Doyle
Journal:  J Am Acad Dermatol       Date:  2004-05       Impact factor: 11.527

9.  Optic neuritis associated with etanercept therapy for juvenile arthritis.

Authors:  Tsivia Tauber; Joseph Turetz; Judith Barash; Isaac Avni; Yair Morad
Journal:  J AAPOS       Date:  2006-02       Impact factor: 1.220

Review 10.  Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592
View more
  7 in total

Review 1.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

2.  The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis.

Authors:  Nicola Pappone; Matteo Nicola Dario Di Minno; Salvatore Iervolino; Roberta Lupoli; Reuven Mader; Carmela Zincarelli; Rosario Peluso
Journal:  Rheumatol Int       Date:  2015-06-06       Impact factor: 2.631

Review 3.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

Review 4.  Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Authors:  Francesco Caso; Luisa Costa; Antonio Del Puente; Matteo Nicola Dario Di Minno; Gelsy Lupoli; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 5.  Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.

Authors:  Arathi Kizhedath; Simon Wilkinson; Jarka Glassey
Journal:  Arch Toxicol       Date:  2016-10-20       Impact factor: 5.153

6.  Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy.

Authors:  Giulia Tadiotto Cicogna; Francesco Messina; Linda Nalotto; Serena Szekely; Mauro Alaibac
Journal:  F1000Res       Date:  2019-03-26

7.  Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.

Authors:  Matteo Nicola Dario Di Minno; Rosario Peluso; Salvatore Iervolino; Anna Russolillo; Roberta Lupoli; Raffaele Scarpa
Journal:  Ann Rheum Dis       Date:  2013-06-14       Impact factor: 19.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.